Skip to main content

Metastatic Non–Small-Cell Lung Cancer with Targetable Mutations

2020 Year in Review - Lung Cancer - Lung Cancer
Geoff Oxnard, MD
Thoracic Medical Oncologist
Foundation Medicine

Dr Geoff Oxnard provides an overview of novel approaches to metastatic NSCLC with targetable mutations, including established and newly discovered molecular targets.

Related Items
Successful Administration of Alectinib Via Gastrojejunostomy Tube for ALK-Positive Non–Small Cell Lung Cancer: A Case Report
JHOP - June 2027 Vol 17, No 3 published on August 11, 2026 in Case Reports, Lung Cancer, Practical Issues in Pharmacy Management, Targeted Therapies
Improving Amivantamab Premedication Compliance by Implementing a Provider Notification
JHOP - February 2027 Vol 17, No 1 published on July 13, 2026 in Original Research, Lung Cancer, Infusion Issues, Oncology Pharmacy Programs/Protocols, Supportive Care
Outcomes of Early Versus Delayed Initiation of Immunotherapy in Patients With Extensive-Stage Small Cell Lung Cancer
JHOP - August 2026 Vol 16, No 4 published on March 11, 2026 in Original Research, Lung Cancer, Immunotherapy, Adverse Events
Impact of Hyperglycemia During Immune Checkpoint Inhibitor Treatment for Advanced Non–Small Cell Lung Cancer: A Retrospective, Single-Center Study
JHOP - June 2026 Vol 16, No 3 published on February 25, 2026 in Original Research, Checkpoint Inhibitors, Adverse Events, Lung Cancer
The Presence of De Novo EGFR T790M Mutation in a Tyrosine Kinase Inhibitor–Naïve Patient with Lung Adenocarcinoma: Case Report and Review of the Literature
JHOP - December 2022 Vol 12, No 6 published on December 20, 2022 in Case Reports, Lung Cancer, Screening, Tyrosine Kinase Inhibitor
Third-Line Tyrosine Kinase Inhibitor Therapy Results in 16-Year Remission in a Patient with Stage IV Non–Small-Cell Lung Cancer
JHOP - August 2022 Vol 12, No 4 published on August 22, 2022 in Case Reports, Lung Cancer, Tyrosine Kinase Inhibitor
2022 Midyear Review: Non–Small-Cell Lung Cancer
JHOP - Supplements published on July 21, 2022 in Lung Cancer
First-Line Sotorasib Shows Long-Lasting Responses in Metastatic NSCLC with KRAS Mutation
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in AACR Highlights, Lung Cancer
Opdivo plus Platinum-Based Chemotherapy FDA Approved as First Neoadjuvant Treatment in Early-Stage NSCLC
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Updates, Lung Cancer, Checkpoint Inhibitors
Severe Adverse Events from Immune Checkpoint Inhibitor Therapy a Rare Concerning Side Effect
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer